Physician profile
Christopher Lee
NPI 1942566443
$475,078.79
in general payments reported to CMS, 2019-2025
22 companies · $125K in 2025
The $125K reported for 2025 was more than what 96% of Orthopaedic Trauma providers received nationally (typical 2025 total: $1,227).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,262 · 2020: $5,514 · 2021: $60K · 2022: $79K · 2023: $88K · 2024: $117K · 2025: $125K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $155K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $88K · Travel and Lodging: $40K · Food and Beverage: $26K · Royalty Or License: $17K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $5,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $154,513.51 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $87,950.00 |
| Travel and Lodging | $39,935.83 |
| Food and Beverage | $26,076.10 |
| Royalty Or License | $16,504.61 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $5,000.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Globus Medical, INC. | $178,010.09 | 2020-2025 | Autobahn, Autobahn, Troch Nail |
| Stryker Corporation | $155,059.19 | 2019-2025 | Axsos, Gamma, Variax |
| Mimedx Group, INC. | $56,309.53 | 2024-2025 | |
| Smith+Nephew, INC. | $54,471.32 | 2019-2024 | Evos, Evos Mini, Trigen Intertan |
| Synthes Gmbh | $16,772.46 | 2021-2025 | |
| Medical Device Business Services, INC. | $8,145.36 | 2020-2022 | |
| Becton, Dickinson and Company | $2,788.51 | 2024 | |
| Depuy Synthes Sales INC. | $931.17 | 2019-2024 | Na, Tfn-Advance |
| Linvatec Corporation | $659.17 | 2020-2023 | Livatec Knee Preservation System |
| Saxum Surgical, INC. | $480.40 | 2023-2024 | |
| Acumed LLC | $368.64 | 2023-2024 | Acumed |
| Inquis Medical, INC. | $325.76 | 2025 | Aventus |
| Djo, LLC | $215.10 | 2020-2023 | Cmf |
| Ipsen Biopharmaceuticals, INC | $130.61 | 2022 | |
| Dynasplint Systems INC. | $130.00 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $125.00 | 2024 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bard Peripheral Vascular, INC. | $55.13 | 2020-2024 | Fluency Endovascular Stent Graft |
| Skeletal Dynamics INC | $26.40 | 2024 | Ijs, Geminus, Implate |
| Acera Surgical, INC. | $24.96 | 2024 | Restrata Wound Matrix |
| Zimmer Biomet Holdings, INC. | $20.00 | 2024 | Affixus |
| Biocomposites INC | $17.88 | 2024 | |
| My01 INC. | $12.11 | 2024 | My01 Continuous Compartmental Pressure Monitor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Lee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.